Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-01
2006-08-01
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S313000, C514S314000, C546S159000, C546S162000, C546S178000
Reexamination Certificate
active
07084156
ABSTRACT:
The present invention is concerned with compounds of the general Formula I:and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.
REFERENCES:
patent: 4013665 (1977-03-01), Crenshaw et al.
patent: 4701459 (1987-10-01), Meanwell et al.
patent: 5942520 (1999-08-01), Pamukcu et al.
patent: 6221613 (2001-04-01), Salon et al.
patent: 6410561 (2002-06-01), Shinkai et al.
patent: 6569861 (2003-05-01), Bakthavatchalam et al.
patent: 6720324 (2004-04-01), Marzabadie et al.
patent: 6727264 (2004-04-01), Marzabadi et al.
patent: 2003/0023085 (2003-01-01), Chen et al.
patent: 2003/0105094 (2003-06-01), Clader et al.
patent: 2003/0144261 (2003-07-01), Palani et al.
patent: 2003/0191136 (2003-10-01), Bakthavatchalam et al.
patent: 2003/0229119 (2003-12-01), Kym et al.
patent: 2004/0006370 (2004-01-01), Cheng et al.
patent: 2004/0106645 (2004-06-01), Blackburn et al.
patent: 0 252 503 (1992-11-01), None
patent: 2001-226269 (2001-08-01), None
patent: 371059 (2002-12-01), None
patent: WO 96/28446 (1996-09-01), None
patent: WO 98/27815 (1998-07-01), None
patent: WO 99/19326 (1999-04-01), None
patent: WO 99/31086 (1999-06-01), None
patent: WO 99/42464 (1999-08-01), None
patent: WO 99/48492 (1999-09-01), None
patent: WO 99/53924 (1999-10-01), None
patent: WO 00/18740 (2000-04-01), None
patent: WO 00/35919 (2000-06-01), None
patent: WO 00/64877 (2000-11-01), None
patent: WO 01/21169 (2001-03-01), None
patent: WO 01/21577 (2001-03-01), None
patent: WO 01/32646 (2001-05-01), None
patent: WO 01/40218 (2001-06-01), None
patent: WO 01/47892 (2001-07-01), None
patent: WO 01/68186 (2001-09-01), None
patent: WO 01/72758 (2001-10-01), None
patent: WO 01/82925 (2001-11-01), None
patent: WO 01/87834 (2001-11-01), None
patent: WO 02/00654 (2002-01-01), None
patent: WO 02/04433 (2002-01-01), None
patent: WO 02/06245 (2002-01-01), None
patent: WO 02/042458 (2002-05-01), None
patent: WO 02/051809 (2002-07-01), None
patent: WO 02/070522 (2002-09-01), None
patent: WO 02/076929 (2002-10-01), None
patent: WO 02/076947 (2002-10-01), None
patent: WO 02/083134 (2002-10-01), None
patent: WO 02/089729 (2002-11-01), None
patent: WO 02/094799 (2002-11-01), None
patent: WO 03/004027 (2003-01-01), None
patent: WO 03/013574 (2003-02-01), None
patent: WO 03/015769 (2003-02-01), None
patent: WO 03/027239 (2003-04-01), None
patent: WO 03/027240 (2003-04-01), None
patent: WO 03/028641 (2003-04-01), None
patent: WO 03/033476 (2003-04-01), None
patent: WO 03/033480 (2003-04-01), None
patent: WO 03/035055 (2003-05-01), None
patent: WO 03/035624 (2003-05-01), None
patent: WO 03/045918 (2003-06-01), None
patent: WO 03/045920 (2003-06-01), None
patent: WO 03/059289 (2003-07-01), None
patent: WO 03/070244 (2003-08-01), None
patent: WO 03/087044 (2003-10-01), None
patent: WO 03/087045 (2003-10-01), None
patent: WO 03/087046 (2003-10-01), None
patent: WO 03/097047 (2003-11-01), None
patent: WO 2004/002987 (2004-01-01), None
Antelman et al., Chem. Abstract, 91:68543, Current Medical Research and Opinion (1979), vol. 6, pp. 73-82, “ The importance of stress in assessing the effects of anorectic drugs”.
Kato et al., Chem. Abstract, 134:266103, “Preparation of N-tetrahydronaphthalenyl carboxamides of melanin concentrating hormone antagonists”.
Mueller et al., Chem. Abstract, 138:4532, “Preparation of quinolines as ligands for the neuropeptide Y receptor useful against arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity”.
Shinkai et al., J. Med. Chem., vol. 43 (2000), pp. 4667-4677, “4-Aminoquinolines: Novel nociceptin antagonist with analgesic activity”.
Lanza et al., J. Med. Chem., vol. 35 (1992), pp. 252-258, “Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding”.
Ganoub, Heterocyclic Communications, vol. 7(2) (2001), pp. 143-148, “A facile approach to N-heterocycles. The reactions of ylide phosphoranes with hydrazones”.
Kowalski et al., Expert Opin. Investig. Drugs, vol. 13(9) (2004), pp. 1113-1122. “Therapeutic potential of melanin-concentrating hormone- 1 receptor antagonists for the treatment of obesity”.
Clark et al., J. Med. Chem., vol. 47 (2004), pp. 3962-3971, “A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone 1 receptor”.
Arienzo et al., Bioorg. & Medicinal Chem. Letters, vol. 14 (2004), pp. 4099-4102, “Structure-activity relationships of a novel series of melanin-concentrating hormone (MCH) receptor antagonists”.
Chang Lehua
Chaung Danny
DeVita Robert J.
Hoang MyLe
Jiang JinLong
Fitch Catherine D.
Merck & Co. , Inc.
Seaman D. Margaret
Winokur Melvin
LandOfFree
2-Aminoquinoline compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-Aminoquinoline compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-Aminoquinoline compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3647379